BR112023016574A2 - Composições de anticorpo anti-tl1a e métodos de tratamento no pulmão - Google Patents
Composições de anticorpo anti-tl1a e métodos de tratamento no pulmãoInfo
- Publication number
- BR112023016574A2 BR112023016574A2 BR112023016574A BR112023016574A BR112023016574A2 BR 112023016574 A2 BR112023016574 A2 BR 112023016574A2 BR 112023016574 A BR112023016574 A BR 112023016574A BR 112023016574 A BR112023016574 A BR 112023016574A BR 112023016574 A2 BR112023016574 A2 BR 112023016574A2
- Authority
- BR
- Brazil
- Prior art keywords
- lung
- treatment methods
- antibody compositions
- tl1a antibody
- tl1a
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163150832P | 2021-02-18 | 2021-02-18 | |
| US202163180896P | 2021-04-28 | 2021-04-28 | |
| US202163226041P | 2021-07-27 | 2021-07-27 | |
| US202163285785P | 2021-12-03 | 2021-12-03 | |
| PCT/US2022/016840 WO2022178158A1 (en) | 2021-02-18 | 2022-02-17 | Anti-tl1a antibody compositions and methods of treatment in the lung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023016574A2 true BR112023016574A2 (pt) | 2023-11-21 |
Family
ID=82931034
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023016574A BR112023016574A2 (pt) | 2021-02-18 | 2022-02-17 | Composições de anticorpo anti-tl1a e métodos de tratamento no pulmão |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240336691A1 (https=) |
| EP (1) | EP4294443A4 (https=) |
| JP (1) | JP2024508762A (https=) |
| KR (1) | KR20230158494A (https=) |
| AU (1) | AU2022221712A1 (https=) |
| BR (1) | BR112023016574A2 (https=) |
| CA (1) | CA3207818A1 (https=) |
| MX (1) | MX2023009681A (https=) |
| TW (1) | TW202302640A (https=) |
| WO (1) | WO2022178158A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI703158B (zh) | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| JP2022533956A (ja) | 2019-05-14 | 2022-07-27 | プロメテウス バイオサイエンシーズ，インク． | Ｔｌ１ａ患者を選択する方法、システム、およびデバイス |
| KR20220103721A (ko) | 2019-10-24 | 2022-07-22 | 프로메테우스 바이오사이언시즈, 인크. | Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도 |
| EP4665394A2 (en) * | 2023-02-17 | 2025-12-24 | Prometheus Biosciences, Inc. | Anti-tl1a antibody compositions and methods of treatment in the kidney |
| EP4665395A1 (en) * | 2023-02-17 | 2025-12-24 | Prometheus Biosciences, Inc. | Anti-tl1a antibody compositions and methods of treatment in the liver |
| AU2024222357A1 (en) * | 2023-02-17 | 2025-08-28 | Cedars-Sinai Medical Center | Anti-tl1a antibody compositions and methods of treating skin |
| WO2024186859A2 (en) * | 2023-03-09 | 2024-09-12 | Prometheus Biosciences, Inc. | Anti-tl1a antibody compositions and methods of treatment for sarcoidosis |
| CN121843714A (zh) | 2023-08-11 | 2026-04-10 | 派拉冈医疗公司 | Tl1a结合抗体及使用方法 |
| US12473370B2 (en) | 2023-10-03 | 2025-11-18 | Absci Corporation | TL1A associated antibody compositions and methods of use |
| TW202545995A (zh) | 2024-01-26 | 2025-12-01 | 大陸商明濟生物製藥(北京)有限公司 | 能夠與ｔｌ１ａ特異性結合之抗體及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080233119A2 (en) * | 2003-08-20 | 2008-09-25 | University Of Miami | Compositions and methods for treating inflammatory lung disease |
| WO2009114110A1 (en) * | 2008-03-08 | 2009-09-17 | Immungene, Inc. | Engineered fusion molecules immunotherapy in cancer and inflammatory diseases |
| JO3375B1 (ar) * | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
| EA201591153A1 (ru) * | 2013-01-02 | 2016-01-29 | Гленмарк Фармасьютикалс С.А. | Антитела, связывающиеся с tl1a, и их применение |
| MX388027B (es) * | 2013-11-13 | 2025-03-19 | Pfizer | Anticuerpos específicos para el ligando 1a tipo factor de necrosis tumoral y composiciones y usos de los mismos. |
| TWI703158B (zh) * | 2015-09-18 | 2020-09-01 | 美商希佛隆公司 | 特異性結合tl1a之抗體 |
| MY191324A (en) * | 2016-10-26 | 2022-06-15 | Cedars Sinai Medical Center | Neutralizing anti-tl1a monoclonal antibodies |
| US10626180B2 (en) * | 2017-04-20 | 2020-04-21 | Cedars-Sinai Medical Center | Methods of treating and predicting non-response to anti-TNF treatment in subjects with inflammatory bowel disease |
| JP7332627B2 (ja) * | 2018-04-25 | 2023-08-23 | プロメテウス バイオサイエンシーズ，インク． | 最適化された抗ｔｌ１ａ抗体 |
| JP2022533956A (ja) * | 2019-05-14 | 2022-07-27 | プロメテウス バイオサイエンシーズ，インク． | Ｔｌ１ａ患者を選択する方法、システム、およびデバイス |
| KR20220103721A (ko) * | 2019-10-24 | 2022-07-22 | 프로메테우스 바이오사이언시즈, 인크. | Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도 |
-
2022
- 2022-02-17 CA CA3207818A patent/CA3207818A1/en active Pending
- 2022-02-17 AU AU2022221712A patent/AU2022221712A1/en active Pending
- 2022-02-17 TW TW111105899A patent/TW202302640A/zh unknown
- 2022-02-17 EP EP22756948.0A patent/EP4294443A4/en active Pending
- 2022-02-17 JP JP2023549819A patent/JP2024508762A/ja active Pending
- 2022-02-17 KR KR1020237031713A patent/KR20230158494A/ko active Pending
- 2022-02-17 WO PCT/US2022/016840 patent/WO2022178158A1/en not_active Ceased
- 2022-02-17 BR BR112023016574A patent/BR112023016574A2/pt unknown
- 2022-02-17 MX MX2023009681A patent/MX2023009681A/es unknown
- 2022-02-17 US US18/546,947 patent/US20240336691A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3207818A1 (en) | 2022-08-25 |
| WO2022178158A1 (en) | 2022-08-25 |
| AU2022221712A1 (en) | 2023-09-21 |
| EP4294443A4 (en) | 2025-08-20 |
| TW202302640A (zh) | 2023-01-16 |
| EP4294443A1 (en) | 2023-12-27 |
| JP2024508762A (ja) | 2024-02-28 |
| KR20230158494A (ko) | 2023-11-20 |
| MX2023009681A (es) | 2023-10-30 |
| US20240336691A1 (en) | 2024-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023016574A2 (pt) | Composições de anticorpo anti-tl1a e métodos de tratamento no pulmão | |
| SA520420801B1 (ar) | أil جسام مضادة لـ -11 | |
| EA202092825A1 (ru) | Анти-sirpa антитела и способы их применения | |
| JOP20190187A1 (ar) | مترافقات عقار جسم مضاد لـ ccr7 | |
| CR20200467A (es) | Agentes anticuerpos anti-cd25 | |
| MX2022002682A (es) | Anticuerpos anti-cd73. | |
| WO2021227307A8 (zh) | 抗cd73抗体及其用途 | |
| EA202190138A1 (ru) | Анти-sirp-бета1 антитела и способы их использования | |
| EA202091130A1 (ru) | Лиофилизованный препарат моноклонального антитела к транстиретину | |
| BR112019008010A2 (pt) | anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica | |
| MA40913A (fr) | Conjugués anticorps-médicament | |
| MX2022001896A (es) | Formulaciones anti-c5 de alta concentracion. | |
| MX2021011715A (es) | Anticuerpos contra amiloide-? con piroglutamato y usos de estos campo de la invención. | |
| EA202191769A1 (ru) | Тубулизины и конъюгаты белок-тубулизин | |
| BR112021008060A2 (pt) | Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento | |
| JOP20230311A1 (ar) | أجسام مضادة لـ sirp-ألفا | |
| CL2022003715A1 (es) | Tubulisinas y conjugados de proteinas-tubulisina | |
| EA202192400A1 (ru) | Антитела против интегрина и их применение | |
| MX2020011027A (es) | Constructos de anticuerpos biespecíficos trivalentes. | |
| EA202091747A1 (ru) | Составы антитела b7-h4 | |
| BR112023002455A2 (pt) | Anticorpos fgfr3 e métodos de uso | |
| MX2021003673A (es) | Anticuerpos anti-vsig4 humano y usos de los mismos. | |
| EA202190183A1 (ru) | Антитела к siglec-5 и способы их применения | |
| BR112021016596A2 (pt) | Anticorpo anti-pd-l1 e uso do mesmo | |
| BR112023020622A2 (pt) | Anticorpo anti-masp2, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo |